Business
Company Presentation
Company Presentation.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n \n \n \n 1 March 2023\n \n \n \n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n (\"Roquefort Therapeutics\" or the \"Company\")\n \n \n \n Company Presentation\n \n \n \n Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\n the Main Market listed biotech company focused on\n developing first in class medicines in the high value and high growth oncology market\n , announces that ahead of its Company Update presentation on the Investor Meeting Company Platform today at 2pm GMT, the presentation is available to download from the Roquefort Therapeutics website at\n \n https://www.roquefortplc.com/category/presentations/\n \n \n \n \n ENDS\n \n \n \n Enquiries:\n \n \n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n \n \n \n \n Stephen West (Chairman) / Ajan Reginald (CEO)\n \n \n \n \n +44 (0)20 3290 9339\n \n \n \n \n \n \n \n \n \n \n Hybridan LLP (Joint Broker)\n \n \n \n Claire Louise Noyce\n \n \n \n \n \n \n \n \n Optiva Securities Limited (Joint Broker)\n \n \n \n \n \n \n \n \n +44 (0)203 764 2341\n \n \n \n \n \n \n Christian Dennis\n \n \n \n \n \n \n Buchanan (Public Relations)\n \n \n \n Ben Romney / Jamie Hooper / George Beale\n \n \n \n \n \n \n \n +44 (0)20 3411 1881\n \n \n \n \n \n \n \n \n +44 (0)20 7466 5000\n \n \n \n \n \n \n \n \n \n \n \n \n LEI: 254900P4SISIWOR9RH34\n \n \n \n \n \n \n \n About Roquefort Therapeutics\n \n \n Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\n \n \n \n \n \n Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.\n \n \n \n \n \n Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of:\n \n \n ·\n Midkine antibodies w...